Trametinib 0.5 mg, 1 mg, 2 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 0.5 mg, 1 mg, 2 mg

Reference Brands: Mekinist (USA/EU)

Category: Oncology Cancer Care

Trametinib is a targeted cancer therapy that inhibits MEK1 and MEK2 enzymes in the MAPK/ERK pathway, helping to slow or stop the growth of cancer cells. It is primarily used for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations and can be combined with BRAF inhibitors for enhanced efficacy.

Product Description:

Trametinib inhibits MEK1 and MEK2, sitting one step below BRAF in the MAPK pathway. Its clinical importance rests on a simple observation: a BRAF inhibitor used alone reliably fails within months because the pathway reactivates beneath the blockade, and adding MEK inhibition both delays that failure and, counter-intuitively, reduces toxicity — the skin lesions caused by paradoxical pathway activation in normal cells become less frequent, not more.

It is used with dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as adjuvant treatment after resection of stage III BRAF-mutant melanoma, for BRAF V600E non-small cell lung cancer and anaplastic thyroid cancer, and across BRAF V600E solid tumours irrespective of site. Pyrexia is characteristic of the combination and can be severe enough to require interruption and steroids. Reduced cardiac ejection fraction, ocular events including retinal vein occlusion, rash and diarrhoea require monitoring.

Sourcing notes. Originator in most territories with generic entry beginning in some — confirm per destination. Three tablet strengths support dose reduction. Always used with a BRAF inhibitor, so quote as a regimen. BRAF V600 testing is mandatory. Tablets require refrigerated storage at 2–8 degrees.